Live Feeds
● LIVE Updated 1h ago · 9 sources tracked

Iovance stock falls after lung cancer trial data disappoints

Shares of Iovance Biotherapeutics plummeted after the company released updated clinical trial results for its cancer therapy, lifileucel. The stock initially crashed sharply before settling into a steep multi-day decline, losing over 35 percent in a single session. Financial institutions responded by lowering price targets on the equity. The selloff was triggered by updated findings from cohorts in a mid-stage trial evaluating the treatment in previously treated lung cancer patients, prompting investor concern despite the presence of certain encouraging subgroup results.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (9)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Iovance Biotherapeutics shares fell 35.76 percent, losing $5.30 to close at $9.52 on Thursday following updated clinical results.
  • ✓ Baird cut its price target on Iovance to $9 from $11 and kept a neutral rating after the stock dropped 35 percent.
  • ✓ Updated data from the Phase 2 IOV-LUN-202 trial showed that 17 of 69 previously treated patients with non-squamous metastatic lung cancer responded to lifileucel, marking a 24.6 percent response rate.
🛡️ Source Corroboration: 9 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Baird reduced its price target for Iovance to $9 from $11 and maintained a neutral rating following a preceding 35 percent drop driven by updated trial results.

Live updates

  1. Iovance Stock Plunges Following Disappointing Lung Cancer Trial Data

    Shares of Iovance Biotherapeutics plummeted after the company released updated clinical trial results for its cancer therapy, lifileucel. The stock initially crashed sharply before settling into a steep multi-day decline, losing over 35 percent in a single session. Financial institutions responded by lowering price targets on the equity. The selloff was triggered by updated findings from cohorts in a mid-stage trial evaluating the treatment in previously treated lung cancer patients, prompting investor concern despite the presence of certain encouraging subgroup results.

    Why it matters

    The sharp market reaction reflects high sensitivity around clinical milestones for leading biotechnology equities. Iovance focuses on tumor-infiltrating lymphocyte therapies, making ongoing trial readouts critical for assessing the commercial viability of its pipeline. Analyst actions following the data release compound the downward pressure on valuation.

    What is confirmed

    • Iovance Biotherapeutics shares fell 35.76 percent, losing $5.30 to close at $9.52 on Thursday following updated clinical results.
    • Baird cut its price target on Iovance to $9 from $11 and kept a neutral rating after the stock dropped 35 percent.
    • Updated data from the Phase 2 IOV-LUN-202 trial showed that 17 of 69 previously treated patients with non-squamous metastatic lung cancer responded to lifileucel, marking a 24.6 percent response rate.

    Still unconfirmed

    • Some market watchers speculated that the stock could face further downside toward a 50 percent total fall.

    What to watch next

    • Additional analyst rating revisions or price target adjustments from Wall Street firms.
    • Further clinical updates or subgroup analyses regarding the Phase 2 IOV-LUN-202 trial for lifileucel.
    Sources used for this update (10)
    1. Investor's Business Daily — Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer Twist
    2. Trefis — Can Iovance Stock Fall 50%?
    3. TradingView — Why Did IOVA Stock Jump Over 10% After-Hours Today?
    4. GlobeNewswire — Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
    5. Yahoo Finance — Iovance stock falls after lung cancer trial data disappoints
    6. finance.yahoo.com — Iovance stock falls after lung cancer trial data disappoints
    7. finance.yahoo.com — Iovance Sinks Another 11% as Baird Cuts Target to $9 After ...
    8. www.rttnews.com — Iovance Biotherapeutics Stock Plunges 36% After Updated Lung ...
    9. www.marketbeat.com — IOVA News Today | Why did Iovance Biotherapeutics stock drop ...
    10. www.tikr.com — Iovance Sinks Another 11% as Baird Cuts Target to $9 After ...
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community